NO20005186D0 - Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor - Google Patents
Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitorInfo
- Publication number
- NO20005186D0 NO20005186D0 NO20005186A NO20005186A NO20005186D0 NO 20005186 D0 NO20005186 D0 NO 20005186D0 NO 20005186 A NO20005186 A NO 20005186A NO 20005186 A NO20005186 A NO 20005186A NO 20005186 D0 NO20005186 D0 NO 20005186D0
- Authority
- NO
- Norway
- Prior art keywords
- enhancement
- administration
- immune responses
- mediated immune
- protein mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8216698P | 1998-04-17 | 1998-04-17 | |
| PCT/US1999/008376 WO1999053958A2 (en) | 1998-04-17 | 1999-04-16 | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005186D0 true NO20005186D0 (no) | 2000-10-16 |
| NO20005186L NO20005186L (no) | 2000-12-14 |
Family
ID=22169464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005186A NO20005186L (no) | 1998-04-17 | 2000-10-16 | Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040033210A1 (no) |
| EP (1) | EP1071469A2 (no) |
| JP (1) | JP2002512204A (no) |
| CN (1) | CN1305387A (no) |
| AU (1) | AU758851B2 (no) |
| BR (1) | BR9909677A (no) |
| CA (1) | CA2328081A1 (no) |
| CZ (1) | CZ20003817A3 (no) |
| HK (1) | HK1038881A1 (no) |
| HU (1) | HUP0101343A3 (no) |
| MX (1) | MXPA00010151A (no) |
| NO (1) | NO20005186L (no) |
| PL (1) | PL343486A1 (no) |
| RU (1) | RU2217168C2 (no) |
| WO (1) | WO1999053958A2 (no) |
| ZA (1) | ZA200005477B (no) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| JP2002511432A (ja) * | 1998-04-15 | 2002-04-16 | レキシジェン ファーマシューティカルズ コーポレイション | 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強 |
| DE69942207D1 (de) * | 1998-08-25 | 2010-05-12 | Merck Patent Gmbh | Expression und export von angiostatin und endostatin als immunofusins |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| AU6227400A (en) * | 1999-07-26 | 2001-02-13 | Childrens Hospital Los Angeles Research Institute | Fenretinide increases antibody cellular toxicity |
| KR100827757B1 (ko) * | 1999-08-09 | 2008-05-07 | 메르크 파텐트 게엠베하 | 복수의 시토킨-항체 복합체 |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| RU2272644C2 (ru) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
| EP1366067B1 (en) * | 2001-03-07 | 2012-09-26 | Merck Patent GmbH | Expression technology for proteins containing a hybrid isotype antibody moiety |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| AU2002308562B2 (en) * | 2001-05-03 | 2008-01-24 | Merck Patent Gmbh | Recombinant tumor specific antibody and use thereof |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| CN104630129A (zh) * | 2002-03-15 | 2015-05-20 | 北卡罗来纳大学查伯山分校 | 原肝干细胞和近肝干细胞 |
| PL211180B1 (pl) * | 2002-12-17 | 2012-04-30 | Merck Patent Gmbh | Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| DE602004013372T2 (de) * | 2003-12-30 | 2009-07-02 | Merck Patent Gmbh | Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung |
| JP2008504008A (ja) * | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| EP1702069A2 (en) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| DE602005016773D1 (de) * | 2004-01-22 | 2009-11-05 | Merck Patent Gmbh | Antikrebs-antikörper mit reduzierter komplementfixierung |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| KR20070085886A (ko) * | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | 감소된 면역원성의 ｉｌ-7 변이체 |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| EP2270050B1 (en) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-CD19 antibodies with reduced immunogenicity |
| WO2007076933A1 (en) * | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
| EA201171259A1 (ru) | 2009-04-22 | 2012-05-30 | Мерк Патент Гмбх | Антительные гибридные белки с модифицированными сайтами связывания fcrn |
| EP3626739A1 (en) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
| DE3812605A1 (de) * | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
| EP1149913A1 (en) * | 1990-11-09 | 2001-10-31 | GILLIES, Stephen D. | Cytokine immunoconjugates |
| ATE208633T1 (de) * | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL127739A0 (en) * | 1996-07-02 | 1999-10-28 | Bar Illan University | Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
-
1999
- 1999-04-16 AU AU35664/99A patent/AU758851B2/en not_active Ceased
- 1999-04-16 CA CA002328081A patent/CA2328081A1/en not_active Abandoned
- 1999-04-16 WO PCT/US1999/008376 patent/WO1999053958A2/en active IP Right Grant
- 1999-04-16 MX MXPA00010151A patent/MXPA00010151A/es unknown
- 1999-04-16 CZ CZ20003817A patent/CZ20003817A3/cs unknown
- 1999-04-16 RU RU2000125522/14A patent/RU2217168C2/ru not_active IP Right Cessation
- 1999-04-16 HU HU0101343A patent/HUP0101343A3/hu unknown
- 1999-04-16 BR BR9909677-3A patent/BR9909677A/pt not_active IP Right Cessation
- 1999-04-16 JP JP2000544361A patent/JP2002512204A/ja active Pending
- 1999-04-16 CN CN99807250A patent/CN1305387A/zh active Pending
- 1999-04-16 PL PL99343486A patent/PL343486A1/xx unknown
- 1999-04-16 EP EP99917576A patent/EP1071469A2/en not_active Ceased
-
2000
- 2000-10-06 ZA ZA200005477A patent/ZA200005477B/en unknown
- 2000-10-16 NO NO20005186A patent/NO20005186L/no not_active Application Discontinuation
-
2002
- 2002-01-18 HK HK02100430.6A patent/HK1038881A1/zh unknown
-
2003
- 2003-05-21 US US10/442,660 patent/US20040033210A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU3566499A (en) | 1999-11-08 |
| HUP0101343A3 (en) | 2003-10-28 |
| HUP0101343A2 (hu) | 2001-08-28 |
| HK1038881A1 (zh) | 2002-04-04 |
| JP2002512204A (ja) | 2002-04-23 |
| EP1071469A2 (en) | 2001-01-31 |
| PL343486A1 (en) | 2001-08-27 |
| MXPA00010151A (es) | 2002-08-06 |
| CZ20003817A3 (cs) | 2002-08-14 |
| CN1305387A (zh) | 2001-07-25 |
| WO1999053958A3 (en) | 1999-12-02 |
| WO1999053958A2 (en) | 1999-10-28 |
| US20040033210A1 (en) | 2004-02-19 |
| NO20005186L (no) | 2000-12-14 |
| RU2217168C2 (ru) | 2003-11-27 |
| ZA200005477B (en) | 2001-11-20 |
| CA2328081A1 (en) | 1999-10-28 |
| BR9909677A (pt) | 2000-12-19 |
| AU758851B2 (en) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20005186D0 (no) | Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor | |
| HUP0101352A3 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor | |
| NO20035426D0 (no) | Fremgangsmåte ved administrering av anti-TNF-D-antistoff | |
| EE200000642A (et) | Suurendatud saagisega FAPalfa-spetsiifilised antikehad | |
| DE69319662D1 (de) | Monoklonale Antikörper gegen GP130-Protein | |
| NO20033387D0 (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
| NO20023788L (no) | Antistoff som binder humant interleukin-18 samt fremgangsmater ved fremstilling og anvendelse derav | |
| DE69627179D1 (de) | Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren | |
| BR0207314B1 (pt) | piscina de onda e mÉtodo de criar méltiplas formaÇÕes de onda. | |
| PL374221A1 (en) | Antibody inhibitors of gdf-8 and uses thereof | |
| BR9611724A (pt) | Inibidor de quinase c de proteína | |
| AU2002316137A1 (en) | Method of determining protein interaction inhibitors | |
| EP0692536A3 (en) | Protein that induces interferon gamma production and monoclonal antibodies against it | |
| DE50207852D1 (de) | Verwendung von fettalkoholethoxylaten als penetrationsförderer | |
| ATE214381T1 (de) | Thiazole derivate als protein kinase c inhibitoren | |
| DE69530078D1 (de) | Antigen/antikörper spezifitätsaustauscher | |
| ATE293477T1 (de) | Neue verwendung von lipase-inhibitoren | |
| HUP0302681A3 (en) | Javelinization of protein antigens to heat shock proteins | |
| ID22650A (id) | Penggunaan penghambat-penghambat lipase usus lambung | |
| MXPA03006817A (es) | Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk). | |
| CY2005003I2 (el) | Mεθοδοι και ενδιαμεσα χρησιμα για κατασκευη αντιφολικων | |
| DE59913213D1 (de) | Verwendung von Copolymerisaten monoethylenisch ungesättigter Carbonsäuren als Solubilisatoren | |
| NO20010464L (no) | FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom | |
| DK0912612T3 (da) | Forenklet fremstilling af bispecifikke antistoffragmenter | |
| DE69709159D1 (de) | Kreuz-dimierisierung von olefinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |